Market Place
Sourcing Support
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Gamida Cell Announces Commencement of Restructuring Process Supported by HCM
27 Mar 2024 //
GLOBENEWSWIRE
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
22 Mar 2024 //
GLOBENEWSWIRE
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
23 Feb 2024 //
GLOBENEWSWIRE
Gamida Cell Actively Pursuing Strategic Alternatives
29 Jan 2024 //
GLOBENEWSWIRE
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
17 Jan 2024 //
GLOBENEWSWIRE
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
27 Nov 2023 //
GLOBENEWSWIRE
Gamida to Present Highlights at the Piper Sandler Annual Conference
20 Nov 2023 //
GLOBENEWSWIRE
Gamida Cell Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Gamida Cell Presents Data on Allogeneic Stem Cell Therapy Omidubicel and GDA-201
04 Nov 2023 //
GLOBENEWSWIRE
Gamida Cell to Report Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Gamida Cell Reports Preliminary Data from Phase 1 Study of GDA-201
16 Oct 2023 //
BUSINESSWIRE
Gamida to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
02 Oct 2023 //
BUSINESSWIRE
Gamida Cell to Present at SITC 38th Annual Meeting
28 Sep 2023 //
BUSINESSWIRE
First Patient Receives Gamida Cell`s Omisirge™ (omidubicel-onlv)
27 Sep 2023 //
BUSINESSWIRE
Gamida Cell to Present Corporate at the H.C. Wainwright 25th Glob Conference
31 Aug 2023 //
BUSINESSWIRE
Gamida Cell to Report Second Quarter 2023 Financial Results
01 Aug 2023 //
BUSINESSWIRE
Gamida Cell To Host Investor Day
14 Jun 2023 //
BUSINESSWIRE
Data To Be Presented on Gamida Cell NK Cell Therapy Candidate GDA-201
31 May 2023 //
BUSINESSWIRE
Gamida Cell to Present Corporate Highlights at Jefferies Healthcare Conference
31 May 2023 //
BUSINESSWIRE
Gamida Cell Appoints Terry Coelho as CFO
22 May 2023 //
BUSINESSWIRE
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
19 Apr 2023 //
BUSINESSWIRE
Gamida Cell stock dips after pricing $23M securities offering
19 Apr 2023 //
SEEKING ALPHA
Gamida Cell Announces Launch of Public Offering of Securities
18 Apr 2023 //
BUSINESSWIRE
FDA clears Gamida`s allogeneic cell therapy Omisirge
18 Apr 2023 //
FDA
Gamida Cell’s Allogeneic Cell Therapy Omisirge® Receives FDA Approval
17 Apr 2023 //
BUSINESSWIRE
Gamida lays off 17%, ditches NKs to keep omidubicel going
28 Mar 2023 //
FIERCE BIOTECH
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
27 Mar 2023 //
BUSINESSWIRE
Gamida Announces Date of Fourth Quarter and Full Year 2022 Financial Results
20 Mar 2023 //
BUSINESSWIRE
Gamida Cell Announces Changes to Board of Directors
20 Mar 2023 //
BUSINESSWIRE
Gamida Cell to Present Highlights at Oppenheimer Annual Healthcare Conference
07 Mar 2023 //
BUSINESSWIRE
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings
18 Feb 2023 //
BUSINESSWIRE
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
12 Dec 2022 //
BUSINESSWIRE
Gamida Cell to Present Highlights at Multiple Upcoming Investor Conferences
23 Nov 2022 //
BUSINESSWIRE
FDA extends deadline to decide on Gamida Cell`s stem cell transplant therapy
23 Nov 2022 //
FIERCEBIOTECH
Gamida Cell Provides Regulatory Update on Omidubicel
21 Nov 2022 //
BUSINESSWIRE
Gamida Cell Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare
10 Nov 2022 //
BUSINESSWIRE
Gamida Cell Announces the Date of Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
Gamida Cell Announces Omidubicel Data To Be Presented as Presentation at ASH
03 Nov 2022 //
BUSINESSWIRE
Data from Omidubicel PIII Trial shows Outcomes for Patients with Blood Cancers
29 Sep 2022 //
BENZINGA
Gamida Announces Entry in Commitment Letter with Highbridge for $25M Financing
28 Sep 2022 //
BUSINESSWIRE
Gamida Cell prices public offering at $20M; Rallybio touts PIb data for RLYB212
28 Sep 2022 //
ENDPTS
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer
19 Sep 2022 //
BUSINESSWIRE
Gamida Presents Data Demonstrating Impact of Transplantation with Omidubicel
12 Sep 2022 //
BUSINESSWIRE
Gamida Cell Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
Gamida Cell Announces Dosing of 1st Patient in Phase 1/2 Study of GDA-201
10 Aug 2022 //
BUSINESS WIRE
Gamida Cell Announces FDA Acceptance of Biologics License Application
01 Aug 2022 //
BUSINESSWIRE
Gamida Cell to Present Corporate Highlights at JMP Securities Conference
13 Jun 2022 //
BUSINESSWIRE
Gamida Cell Completes Rolling BLA Submission to FDA for Omidubicel
02 Jun 2022 //
BUSINESSWIRE
Gamida Cell to Enroll in Company-Sponsored PI/II Study of GDA-201
01 Jun 2022 //
BUSINESSWIRE
Gamida Cell to Present Corporate Highlights at Jefferies Healthcare Conference
01 Jun 2022 //
BUSINESSWIRE
Gamida Cell Reports First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified NK Pipeline
05 May 2022 //
BUSINESSWIRE
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting
25 Apr 2022 //
BUSINESSWIRE
Gamida Cell Presents Updated Omidubicel Data During Best Abstract
25 Apr 2022 //
BUSINESSWIRE
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion
07 Apr 2022 //
BUSINESSWIRE
Gamida Cell Reports Q4 and FY 2021 Financial Results and Provides Company Update
15 Mar 2022 //
BUSINESSWIRE
